Modafinil effects during acute continuous positive airway pressure withdrawal: A randomized crossover double-blind placebo-controlled trial

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 8, 2010, Pages 825-831

  Williams, Shaun C ^a   Marshall, Nathaniel S ^a   Kennerson, Marina ^b,c,d   Rogers, Naomi L ^e   Liu, Peter Y ^a,f   Grunstein, Ronald R ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b ANZAC RESEARCH INSTITUTE   (Australia)

^c University of Sydney   (Australia)

^d Molecular Medicine Laboratory   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Continuous positive airway pressure; Modafinil; Obstructive sleep apnea; Withdrawal

Indexed keywords

MODAFINIL; PLACEBO; BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT;

ADULT; ALERTNESS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG EFFECT; HUMAN; MALE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SIMULATION; SLEEP APNEA SYNDROME; SOMNOLENCE; TREATMENT WITHDRAWAL; ARTIFICIAL VENTILATION; CAR DRIVING; METHODOLOGY; MIDDLE AGED; REACTION TIME; STATISTICS; TRAFFIC ACCIDENT; WAKEFULNESS;

ACCIDENTS, TRAFFIC; AUTOMOBILE DRIVING; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CONTINUOUS POSITIVE AIRWAY PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SLEEP APNEA SYNDROMES; VENTILATOR WEANING; WAKEFULNESS;

EID: 77953030826     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200908-1307OC     Document Type: Article

References (41)

1. Terán-Santos J, Jiménez-Gómez A, Cordero-Guevara J. The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. N Engl J Med 1999;340:847-851.
2. George C. Reduction in motor vehicle collisions following treatment of sleep apnoea with nasal CPAP. Thorax 2001;56:508-512.
3. Ellen R, Marshall S, Palayew M, Molnar F, Wilson K, Man-Son-Hing M. Systematic review of motor vehicle crash risk in persons with sleep apnea. J Clin Sleep Med 2006;2:193-200. (Pubitemid 43893272)
4. Weaver T, Grunstein R. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 2008;5:173-178.
5. Howard M, Desai A, Grunstein R, Hukins C, Armstrong J, Joffe D, Swann P, Campbell D, Pierce R. Sleepiness, sleep-disordered breathing, and accident risk factors in commercial vehicle drivers. Am J Respir Crit Care Med 2004;170:1014-1021.
6. Yang Q, Phillips CL, Melehan KL, Rogers NL, Seale JP, Grunstein RR. Effects of short-term CPAP withdrawal on neurobehavioral performance in patients with obstructive sleep apnea. Sleep 2006;29:545-552.
7. Kribbs NB, Pack AI, Kline LR, Getsy JE, Schuett JS, Henry JN, Maislin G, Dinges DF. Effects of one night without nasal cpap treatment on sleep and sleepiness in patients with obstructive sleep apnea. Am Rev Respir Dis 1993;147:1162-1168.
8. Minzenberg M, Carter C. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008;33:1477-1502.
9. Bonnet MH, Balkin TJ, Dinges DF, Roehrs T, Rogers NL, Wesensten NJ. The use of stimulants to modify performance during sleep loss: a review by the sleep deprivation and stimulant task force of the American Academy of Sleep Medicine. Sleep 2005;28:1163-1187.
10. Sahakian B, Morein-Zamir S. Professor's little helper. Nature 2007;450: 1157-1159.
11. Pack AI. Should a pharmaceutical be approved for the broad indication of excessive sleepiness? Am J Respir Crit Care Med 2003;167:109-111.
12. Williams SC, Rogers NL, Marshall NS, Leung S, Starmer GA, Grunstein RR. The effect of modafinil following acute CPAP withdrawal: a preliminary study. Sleep Breath 2008;12:359-364.
13. Williams SC, Marshall NS, Kennerson M, Liu PY, Rogers NL, Grunstein RR. Modafinil effects during acute cpap withdrawal: a randomised crossover double-blind placebo-controlled trial [abstract]. Sleep Biol Rhythms 2009;7:A41.
14. Williams SC, Marshall NS, Liu PY, Rogers NL, Grunstein RR. Modafinil effects during acute cpap withdrawal: a randomised crossover doubleblind placebo-controlled trial [abstract]. Sleep 2009;32:A209.
15. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545.
16. Banks S, Catcheside P, Lack L, Grunstein RR, McEvoy RD. Low levels of alcohol impair driving simulator performance and reduce perception of crash risk in partially sleep deprived subjects. Sleep 2004;27: 1063-1067.
17. Dinges D, Powell J. Microcomputer analyses of performance on a portable, simple visual rt task during sustained operations. Behav Res Methods Instrum Comput 1985;17:652-655.
18. Rofail-Makarie L, Wong KK, Unger G, Grunstein R. The in-laboratory validation of a portable flow monitor for OSA diagnosis. Sleep Biol Rhythms 2007;5:A110-A189.
19. Johns MW. Daytime sleepiness, snoring, and obstructive sleep apnea: the Epworth Sleepiness Scale. Chest 1993;103:30-36.
20. Akerstedt T, Hume K, Minors D, Waterhouse J. The subjective meaning of good sleep, an intraindividual approach using the Karolinska Sleep Diary. Percept Mot Skills 1994;79:287-296.
21. Desai A, Wilsmore B, Bartlett D, Unger G, Constable B, Joffe D, Grunstein R. The utility of the AusEd driving simulator in the clinical assessment of driver fatigue. Behav Res Methods 2007;39: 673-681.
22. Vakulin A, Baulk S, Catcheside P, Antic N, van den Heuvel C, Dorrian J, McEvoy R. Effects of alcohol and sleep restriction on simulated driving performance in untreated patients with obstructive sleep apnea. Ann Intern Med 2009;151:447-455.
23. Gillberg M, Kecklund G, Akerstedt T. Relations between performance and subjective ratings of sleepiness during a night awake. Sleep 1994; 17:236-241.
24. Hack M, Davies RJ, Mullins R, Choi SJ, Ramdassingh-Dow S, Jenkinson C, Stradling JR. Randomised prospective parallel trial of therapeutic versus subtherapeutic nasal continuous positive airway pressure on simulated steering performance in patients with obstructive sleep apnoea. Thorax 2000;55:224-231.
25. Pocock SJ. Clinical trials: a practical approach. West Sussex, NY: Wiley; 1983.
26. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178-S189.
27. Dinges DF, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with NCPAP. Sleep Med 2003;4:393-402.
28. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005;28:464-471.
29. Pack AI, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001;164:1675-1681.
30. Pigeau R, Naitoh P, Buguet A, McCann C, Baranski J, Taylor M, Thompson M, Mac KII. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995;4:212-228.
31. Pack A, Pack A, Rodgman E, Cucchiara A, Dinges D, Schwab C. Characteristics of crashes attributed to the driver having fallen asleep. Accid Anal Prev 1995;27:769-775.
32. MarketStrat Inc. Sleep apnea diagnostic and therapeutic devices worldwide. Dublin, California: MarketStrat Inc; August 2008.
33. Kribbs NB, Pack AI, Kline LR, Smith PL, Schwartz AR, Schubert NM, Redline S, Henry JN, Getsy JE, Dinges DF. Objective measurement of patterns of nasal cpap use by patients with obstructive sleep apnea. Am Rev Respir Dis 1993;147:887-895.
34. Baranski J, Pigeau R, Dinich P, Jacobs I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 2004;19:323-332.
35. Gurtman C, Broadbear J, Redman J. Effects of modafinil on simulator driving and self-assessment of driving following sleep deprivation. Hum Psychopharmacol 2008;23:681-692.
36. Kingshott RN, Vennelle M, Coleman EL, Engleman HM, Mackay TW, Douglas NJ. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001;163:918-923.
37. Marin J, Carrizo S, Vicente E, Agusti A. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-1053.
38. Yaggi H, Concato J, Kernan W, Lichtman J, Brass L, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034-2041.
39. Lavie P, Lavie L. Cardiovascular morbidity and mortality in obstructive sleep apnea. Curr Pharm Des 2008;14:3466-3473.
40. Marshall N, Wong K, Liu P, Cullen S, Knuiman M, Grunstein R. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008;31:1079-1085.
41. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-1239. (Pubitemid 34461732)